Blog

Let’s Discover the Future of Novel Drugs and Technologies Together! Discovery on Target (DOT) 2021 Discovery on Target (DOT) is an industrial preeminent event on novel drug targets and technologies for drug discovery professionals. DOT highlights advances in the current and emerging “hot” targets and technologies, as well as target validation strategies for the discoveryRead more

On the September 18th to 19th, the Smart China Expo’s important series of events, “2021 Conference on High Quality Development of Healthcare Industry and the 6th China Pharmaceutical R&D Innovation Summit” kicked off at Chongqing, China. Shanghai Medicilon Inc. (Medicilon) was invited to participate in this event and was awarded the “Top Chinese R&D CRORead more

Medicilon attended the 21st China International Fair for Investment and Trade and signed a strategic collaboration agreement with Xiamen Biotime. The 21st China International Fair for Investment and Trade On September 8th to 11th, the 21st China International Fair for Investment and Trade (CIFIT) was held in Xiamen, Fujian Province. As the leading one-stop preclinicalRead more

With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop.  From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again.  In recent years, the exploration of IL-23 by new drug developers has never stopped. IL-23 MechanismRead more

Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg, PhD Fellow, Sanofi Presentation: “A semi-synthetic organism that stores and retrieves increased genetic information” 9:45 am Anthony Sun, PhD Presentation: “So you want to start a biotech?The Zentalis Story fromRead more

During September 2 to 7, the 2021 China International Fair for Trade in Services (CIFTIS) co-sponsored by the Ministry of Commerce and the Beijing Municipal Government was held in Beijing.  In the service demonstration case selection, Shanghai Medicilon Inc. (Medicilon) “Internet + One-Stop Preclinical R&D Service Platform” was awarded the “Science and Technology Innovation ServiceRead more

Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department. Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department Dr. Hong Wan, PhD in analytical chemistry from Stockholm University, Sweden, has more than 20 years’ experience in Drug Discovery andRead more

Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration agreement to jointly discover, develop and commercialize a series of innovative small molecule drug candidates that cause tumor-specific immune responses. As a collaborative partner of Kumquat, Shanghai Medicilon Inc. (Medicilon)Read more

On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at Chuansha Park for examination.  Professor Shuangqing Peng, CSO of Medicilon; Yaoliang Zhang, Director of the Administration Department; and Nanmei Zhou, Director of the Public Affairs accompanied the examination and organizedRead more

Recently, Shanghai Ringene Biopharma (Ringene) announced that the company’s self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical use. Shanghai Medicilon Inc. (Medicilon) provides a range of preclinical services from drug targets to IND filing in the development of RG001 tablets to enter the clinical trial phase, includingRead more